Elicio Therapeutics, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company developing a pipeline of investigational cancer immunotherapies built on its Amphiphile (AMP) platform. This news page aggregates company press releases and market-moving updates related to Elicio’s clinical programs, platform research, and corporate developments.

Recent news from Elicio has focused on its lead program ELI-002, an AMP-based, off-the-shelf immunotherapy targeting cancers driven by KRAS mutations. The company regularly reports immunogenicity data from the Phase 2 AMPLIFY-7P trial in mKRAS pancreatic ductal adenocarcinoma, including mKRAS-specific T cell response rates, CD4 and CD8 activation, antigen spreading to non-mKRAS neoantigens, and analyses across diverse HLA backgrounds. These updates provide insight into how ELI-002 7P may elicit broad, mutation-directed immune responses in high-risk patients.

In addition to clinical readouts, Elicio’s news flow includes announcements about preclinical findings for intratumoral ELI-004, presentations at scientific meetings such as the Society for Immunotherapy of Cancer and ESMO Immuno-Oncology Congress, and investigator-initiated trials combining ELI-002 7P with chemotherapy and checkpoint inhibitors in pancreatic cancer. Corporate updates, including financial results, cash runway commentary, and executive appointments, also feature prominently in the company’s disclosures.

Investors and observers following ELTX news can use this page to review Elicio’s latest statements on its AMP platform, off-the-shelf immunotherapy strategy, and development plans in mKRAS-positive pancreatic and colorectal cancers, as well as emerging programs targeting BRAF and p53 mutations. Bookmark this feed to monitor new trial data, regulatory-related communications, and other material events reported by the company.